Affiris AG of Austria has received $1.5 million from the Michael J. Fox Foundation in the US to start a Phase 1 study of a new vaccine for Parkinson’s disease. The therapeutic vaccine candidate targets the protein, alpha-synuclein. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals